# Odyssey Therapeutics Inc. (ODTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $28.76, market value $1.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Odyssey Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 480.4×**. Each dollar of revenue is priced at 480.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 3.3×**. The shares trade at 3.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -10.8%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 30.4%**. 30.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 21.7%**. Return on all capital, debt included, is 21.7%: comfortably above what that capital costs.
- **Return on assets: -63.3%**. Each dollar of assets produces -63.3% of profit.

## Growth
- **Revenue growth (1 yr): -33.5%**. Revenue fell 33.5% over the last year.
- **EPS growth (1 yr): -13.9%**. Earnings per share fell 13.9%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Net debt / EBITDA: 0.9×**. It would take 0.9 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 7.20** (quick 7.20). Current assets cover the next year's liabilities 7.20 times.
- **Altman Z-score: -2.67**. A Z-score of -2.67 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Odyssey Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (4 analysts). 4 analysts cover Odyssey Therapeutics Inc.; the consensus is strong_buy, with an average price target of $35.75 (+24% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -1.0%** (90.5% above the low). Trading within 5% of its 52-week high.
- **RSI (14-day): 72**. An RSI of 72 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 1.37** (volatility 65%). Beta of 1.37 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ODTX · Page: https://foliofundamentals.com/stocks/odtx

Not investment advice.